UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2155) 2155
humans (2083) 2083
life sciences & biomedicine (2056) 2056
male (1282) 1282
animals (1261) 1261
female (947) 947
benzamides - pharmacokinetics (944) 944
imatinib mesylate (936) 936
benzamides (861) 861
pharmacology & pharmacy (806) 806
benzamides - pharmacology (763) 763
adult (657) 657
oncology (652) 652
middle aged (589) 589
mice (508) 508
rats (487) 487
pyrimidines - therapeutic use (485) 485
piperazines - therapeutic use (473) 473
benzamides - therapeutic use (457) 457
aged (423) 423
antineoplastic agents - therapeutic use (419) 419
benzamides - administration & dosage (384) 384
imatinib (358) 358
dose-response relationship, drug (357) 357
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (344) 344
pyrimidines - pharmacokinetics (320) 320
piperazines - pharmacokinetics (311) 311
benzamides - chemistry (303) 303
piperazines - pharmacology (298) 298
hematology (290) 290
treatment outcome (289) 289
pyrimidines - pharmacology (288) 288
antineoplastic agents - pharmacokinetics (281) 281
administration, oral (270) 270
antineoplastic agents - pharmacology (268) 268
cancer (253) 253
benzamides - adverse effects (249) 249
pyrimidines - administration & dosage (248) 248
neurosciences & neurology (240) 240
cell line, tumor (236) 236
piperazines - administration & dosage (233) 233
neurosciences (229) 229
research (226) 226
pharmacokinetics (223) 223
chemistry (217) 217
analysis (213) 213
physical sciences (209) 209
drug therapy (208) 208
rats, sprague-dawley (207) 207
medicine & public health (205) 205
protein kinase inhibitors - therapeutic use (196) 196
pyrimidines - adverse effects (188) 188
benzamides - blood (184) 184
tissue distribution (184) 184
young adult (184) 184
chronic myeloid leukemia (182) 182
care and treatment (179) 179
antineoplastic agents - administration & dosage (178) 178
biochemistry & molecular biology (176) 176
protein-tyrosine kinases - antagonists & inhibitors (174) 174
aged, 80 and over (173) 173
brain - metabolism (170) 170
structure-activity relationship (169) 169
antineoplastic agents - adverse effects (168) 168
piperazines - adverse effects (168) 168
antineoplastic agents (166) 166
benzamides - metabolism (164) 164
abridged index medicus (162) 162
benzamides - chemical synthesis (157) 157
adolescent (156) 156
pharmacology/toxicology (156) 156
antimitotic agents (150) 150
protein kinase inhibitors - pharmacology (150) 150
drug interactions (148) 148
drug resistance, neoplasm (148) 148
time factors (148) 148
pyrrolidines - pharmacokinetics (145) 145
leukemia (144) 144
receptors, dopamine d2 - metabolism (140) 140
gastrointestinal stromal tumors - drug therapy (137) 137
disease models, animal (136) 136
tumors (135) 135
brain - diagnostic imaging (134) 134
pharmacology (134) 134
cell proliferation - drug effects (131) 131
health aspects (128) 128
mutation (124) 124
chemistry, medicinal (123) 123
neoplasms - drug therapy (123) 123
piperazines - blood (123) 123
pyrimidines - blood (120) 120
radiopharmaceuticals - pharmacokinetics (118) 118
biological availability (116) 116
psychiatry (115) 115
proteins (114) 114
research article (114) 114
kinases (113) 113
drug administration schedule (112) 112
clinical trials (110) 110
toxicology (110) 110
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2774) 2774
Japanese (29) 29
French (13) 13
German (12) 12
Spanish (9) 9
Chinese (8) 8
Russian (8) 8
Italian (3) 3
Danish (2) 2
Czech (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical pharmacokinetics, ISSN 0312-5963, 2005, Volume 44, Issue 9, pp. 879 - 894
.... Pharmacokinetic studies of imatinib in healthy volunteers and patients with CML, GIST and other cancers show that orally administered imatinib is well absorbed, and has an absolute bioavailability of 98... 
Imatinib | Tyrosine kinase inhibitors | Antineoplastics | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Tissue Distribution | Absorption | Animals | Drug Interactions | Microdialysis | Humans | Pyrimidines - pharmacokinetics | Metabolic Clearance Rate | Benzamides | Piperazines - pharmacokinetics | Imatinib Mesylate | Index Medicus
Journal Article
Journal Article
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2009, Volume 35, Issue 8, pp. 692 - 706
.... Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment... 
Hematology, Oncology and Palliative Medicine | Excretion | Absorption | Metabolism | Tyrosine kinase inhibitors | Distribution | Drug transporters and interactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Pyrroles - pharmacokinetics | Humans | Cytochrome P-450 Enzyme System - metabolism | Pyridines - pharmacokinetics | Quinazolines - pharmacokinetics | Biological Availability | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Tissue Distribution | Benzenesulfonates - pharmacokinetics | Drug Interactions | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Administration, Oral | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Oncology, Experimental | Cytochrome P-450 | Physiological aspects | Phenols | Research | Phosphotransferases | Protein binding | Cancer | Index Medicus
Journal Article
European journal of clinical pharmacology, ISSN 1432-1041, 10/2012, Volume 69, Issue 4, pp. 813 - 823
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 05/2010, Volume 28, Issue 14, pp. 2381 - 2388
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article